Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/223121 
Year of Publication: 
2020
Citation: 
[Journal:] economic sociology_the european electronic newsletter [ISSN:] 1871-3351 [Volume:] 21 [Issue:] 3 [Publisher:] Max Planck Institute for the Study of Societies (MPIfG) [Place:] Cologne [Year:] 2020 [Pages:] 11-19
Publisher: 
Max Planck Institute for the Study of Societies (MPIfG), Cologne
Abstract: 
The stakes around the global and national medicines markets have been rising steadily for the last twenty years. From the controversies over patents surrounding HIV treatments and the right of developing countries to infringe these patents and develop generic copies in the late 1990s ('t Hoen 2002; Coriat 2008), to the current debates over the exorbitant prices of certain medicines and the sustainability of the expenditure they generate for national health insurance (Vogler et al. 2016), or, in the current context of the Covid-19 pandemic, over supply disruptions and struggles between countries to access treatments, tests, and protective masks - medicines and health products raise a series of fundamental questions.
Document Type: 
Article

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.